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Adjuvant therapy following oesophagectomy for
adenocarcinoma in patients with a positive resection margin
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Background: The role of adjuvant therapy in patients with oesophagogastric adenocarcinoma treated
by neoadjuvant chemotherapy is contentious. In UK practice, surgical resection margin status is often
used to classify patients for receiving adjuvant treatment. The aim of this study was to assess the survival
benefit of adjuvant therapy in patients with positive (R1) resection margins.
Methods: Two prospectively collected UK institutional databases were combined to identify eligible
patients. Adjusted Cox regression analyses were used to compare overall and recurrence-free survival
according to adjuvant treatment. Recurrence patterns were assessed as a secondary outcome. Propensity
score-matched analysis was also performed.
Results: Of 616 patients included in the combined database, 242 patients who had an R1 resection
were included in the study. Of these, 112 patients (46⋅3 per cent) received adjuvant chemoradiotherapy,
46 (19⋅0 per cent) were treated with adjuvant chemotherapy and 84 (34⋅7 per cent) had no adjuvant
treatment. In adjusted analysis, adjuvant chemoradiotherapy improved recurrence-free survival (hazard
ratio (HR) 0⋅59, 95 per cent c.i. 0⋅38 to 0⋅94; P= 0⋅026), with a benefit in terms of both local (HR 0⋅48,
0⋅24 to 0⋅99; P= 0⋅047) and systemic (HR 0⋅56, 0⋅33 to 0⋅94; P= 0⋅027) recurrence. In analyses stratified
by tumour response to neoadjuvant chemotherapy, non-responders (Mandard tumour regression grade
4–5) treated with adjuvant chemoradiotherapy had an overall survival benefit (HR 0⋅61, 0⋅38 to 0⋅97;
P= 0⋅037). In propensity score-matched analysis, an overall survival benefit (HR 0⋅62, 0⋅39 to 0⋅98;
P= 0⋅042) and recurrence-free survival benefit (HR 0⋅51, 0⋅30 to 0⋅87; P= 0⋅004) were observed for
adjuvant chemoradiotherapy versus no adjuvant treatment.
Conclusion: Adjuvant therapy may improve overall survival and recurrence-free survival after
margin-positive resection. This pattern seems most pronounced with adjuvant chemoradiotherapy in
non-responders to neoadjuvant chemotherapy.
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Introduction
Although survival rates have improved, oesophageal can-
cer is still an important cause of cancer-related deaths
worldwide1. Oesophageal adenocarcinoma is an aggres-
sive disease and most patients have locally advanced or
metastatic disease at presentation2. Despite advances in
staging and oncological therapies, long-term outcomes
after surgical treatment for oesophageal cancer remain
relatively poor3.
Over the past decade, UK practice has been influenced
by a number of large clinical trials4–8 that have demon-
strated a significant survival benefit for patients treated
with neoadjuvant therapy compared with surgery alone.
The MAGIC4 and FLOT (5-fluorouracil (5-FU), leucov-
orin, oxaliplatin and docetaxel)8 trials both demonstrated
a benefit for perioperative chemotherapy, but the specific
gains afforded by adjuvant treatment remain unknown. In
addition, only 50 per cent of patients scheduled for postop-
erative treatment completed chemotherapy, largely owing
to the accumulation of acquired therapeutic toxicities4.
According to the National Oesophago-Gastric Cancer
Audit, most patients in the UK are offered neoadjuvant
chemotherapy, rather than neoadjuvant chemoradiother-
apy, although trials9,10 comparing the two strategies are
in progress. In patients with a microscopically positive
resection margin (R1 resection), which occurs in 28–40
per cent of patients11,12 when the Royal College of Pathol-
ogists (RCP) definition is used, survival is worse13,14.
Adjuvant chemoradiotherapy is generally recommended
in this group, provided that the patient is fit enough
to withstand treatment15. However, prospective clinical
trials are required to establish the benefit of adjuvant
treatments in the context of neoadjuvant chemotherapy
and for their role in current treatment protocols to be
confirmed.
The aim of this study was to assess the survival ben-
efit of current adjuvant treatments in patients who had
margin-positive resection treated in two high-volume ter-
tiary referral centres in the UK.
Methods
This was a retrospective cohort study of patients with
oesophageal and gastro-oesophageal junctional adeno-
carcinoma using an ethically approved, collaborative
database, from two UK-based institutions: St Thomas’
Hospital and the Royal Marsden Hospital in London. Both
are high-volume tertiary referral centres which provide
specialist surgical and oncological care. The database
combined two prospectively maintained, hospital-based
operative registries of all patients undergoing oesophago-
gastrectomy for cancer.
Study cohort
All patients who underwent surgical resection for
oesophageal adenocarcinoma between January 2006
and December 2016 were identified from the collaborative
database. All included patients had at least 12 months
of complete follow-up data. Patients who died in hos-
pital or within 30 days of surgery were excluded. All
patients were discussed in a specialist oesophagogastric
cancer multidisciplinary team (MDT) meeting. Stan-
dard staging investigations included endoscopy, CT,
endoscopic ultrasound imaging, PET–CT and staging
laparoscopy in selected patients. Transthoracic and trans-
hiatal oesophageal resections were performed, dictated by
tumour location, at the discretion of the individual sur-
geon. All resection specimens were examined by specialist
gastrointestinal pathologists and the status of the resection
margin was classified according to RCP criteria16; an R0
resection was defined by no involvement of any margin,
and an R1 resection by tumour within 1 mm of the cut
margin. All patients with positive margins (R1 resection)
were included in the present analysis. Some patients were
also assessed using the College of American Patholo-
gists (CAP) R1 definition of tumour at the cut resection
margin17. All patients were allocated a tumour regression
grade (TRG) according to the Mandard classification18.
Patients with a TRG of 1–3 were considered to have had
a response to neoadjuvant chemotherapy (responders) and
those with a TRG of 4 and 5 were considered not to have
responded (non-responders).
Treatment
The neoadjuvant chemotherapy regimens included CF
(cisplatin and 5-FU), ECF (epirubicin, cisplatin, 5-FU),
ECX (epirubicin, cisplatin and capecitabine) and EOX
(epirubicin, oxaliplatin and capecitabine), and most
patients completed the standard two to four cycles, in
accordance with randomized trial evidence available at the
time of treatment. Patients with positive margins (R1 resec-
tion) were subcategorized by adjuvant treatment group:
adjuvant chemoradiotherapy, adjuvant chemotherapy
alone or no adjuvant treatment. Tumour stage, response
to neoadjuvant treatment, tolerance of chemotherapy and
patient fitness were taken into account by the MDT. The
adjuvant chemotherapy regimens included CF, ECF, ECX
and EOX, and most patients completed three or fewer
cycles. Radiotherapy in combination with chemotherapy
was given as 45 Gy in 25 fractions or 50 Gy in 28 fractions.
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 1801–1810
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Outcome measures
Overall survival time was the interval from the date of sur-
gical resection until the date of death. Time to recurrence
was calculated from the date of surgical resection until
disease recurrence, defined as either histopathological
or definitive radiological evidence of local recurrence,
systemic recurrence or both. Recurrence patterns were
assessed as a secondary outcome. In the absence of
recurrence, survival was calculated to the last confirmed
attendance at a hospital or general practitioner clinic.
Statistical analysis
Basic demographic, surgical and oncological data were
evaluated using descriptive statistics. The Kaplan–Meier
method with log rank test was used to calculate and com-
pare survival. Cox proportional hazards regression analysis
(crude and adjusted) was used to calculate hazard ratios
(HRs) with 95 per cent confidence intervals to model the
association between the study outcomes (risk of all-cause
mortality and risk of recurrence) according to the study
exposure (adjuvant treatment). Co-variables included in the
multivariable models were: age (continuous), sex, tumour
location (oesophageal, Siewert 1, Siewert 2), pathological T
category (pT0–2, pT3–4), pathological N category (pN0,
pN1, pN2, pN3), lymphovascular invasion, postoperative
differentiation (well/moderate, poor), operative approach
(Ivor Lewis oesophagectomy, transhiatal oesophagectomy,
left thoracoabdominal oesophagectomy) and response to
neoadjuvant chemotherapy (TRG 1–3, TRG 4 and 5).
To explore whether the effects of adjuvant therapy dif-
fered according to response to neoadjuvant chemother-
apy, separate analyses were undertaken for responders and
non-responders. Cox regression analyses comparing over-
all survival and recurrence-free survival, according to dif-
ferent adjuvant therapies, were also conducted using data
from propensity score-matched cohorts. Propensity scores
for receipt of adjuvant therapies were derived using logit
models based on the same variables as the Cox regression
models (Table S1, supporting information). Matching was
done using the psmatch2 module in Stata, with a caliper of
0⋅1 and non-replacement. P < 0⋅050 was used to define sta-
tistical significance for all outcomes. All statistical analysis
was performed using Stata version 15 (StataCorp, College
Station, Texas, USA).
Results
Patient demographics, clinical characteristics and neoad-
juvant treatment details are summarized in Table 1.
The database included 616 consecutive patients with
oesophageal adenocarcinoma, of whom 242 (39⋅3 per cent)
with positive margins (R1 resection), by RCP criteria, were
included in the present study. This was equivalent to a
14⋅9 per cent R1 resection rate according to the CAP clas-
sification. Among the 242 patients who had R1 resections,
204 (84⋅3 per cent) had a positive circumferential resection
margin, seven (2⋅9 per cent) had a positive longitudinal
margin, and 29 (12⋅0 per cent) had both. Median follow-up
was 25 months among patients who survived compared
with 11 months for those who died.
In total, 220 patients (90⋅9 per cent) received neoad-
juvant chemotherapy, all of whom were scheduled for
adjuvant treatment based on intention to treat; 46 patients
(20⋅9 per cent) were deemed to be responders (TRG 1–3)
and 168 (76⋅4 per cent) were non-responders (TRG 4
and 5). The patients were categorized into three adjuvant
treatment groups; 112 patients (46⋅3 per cent) received
adjuvant chemoradiotherapy, 46 (19⋅0 per cent) had adju-
vant chemotherapy alone and 84 (34⋅7 per cent) did not
have adjuvant treatment. Among those who received
adjuvant chemotherapy alone, most were scheduled for
chemoradiotherapy by MDT consensus, but patient fitness
or inability to tolerate radiotherapy meant that they only
received chemotherapy.
Deaths
The 30-day mortality rate for the whole cohort was
less than 1 per cent (6 deaths among 616 patients). The
in-hospital mortality rate after surgical resection was 1⋅6
per cent (10 deaths) and these patients were excluded from
the analyses.
Overall survival
Kaplan–Meier curves for overall survival, according to
adjuvant therapy type, are shown in Fig. 1. Survival at
3 years was improved after adjuvant treatment (39⋅0, 40
and 25 per cent in adjuvant chemoradiotherapy, adjuvant
chemotherapy and no adjuvant treatment groups).
Results of crude and adjusted Cox regression analyses are
shown in Table 2 and Table S2 (supporting information).
Pathological N3 status (HR 3⋅03, 95 per cent c.i. 1⋅51 to
4⋅58; P < 0⋅001) and poor differentiation (HR 1⋅56, 1⋅06 to
2⋅28; P= 0⋅024) were independently associated with overall
survival. For all patients who had a margin-positive resec-
tion, although the HRs favoured adjuvant treatment, these
did not reach statistical significance (adjuvant chemora-
diotherapy: HR 0⋅71, 0⋅47 to 1⋅06, P= 0⋅097; adjuvant
chemotherapy: HR 0⋅64, 0⋅39 to 1⋅04, P= 0⋅072). In analy-
ses stratified by tumour response to neoadjuvant treatment,
a survival benefit was observed in non-responders (TRG 4
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 1801–1810
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Table 1 Patient demographics, clinical characteristics and neoadjuvant treatment details for all patients who underwent
margin-positive resection
No adjuvant




(n = 46) P‡
Age (years)* 65 (58–70) 62 (54–68) 63 (56–69) 0⋅027§
Sex ratio (M : F) 64 : 20 93 : 19 39 : 7 0⋅235
Tumour location Oesophageal – mid–low 13 (15) 38 (33⋅9) 12 (26) 0⋅001
GOJ – Siewert 1 26 (31) 34 (30⋅4) 16 (35)
GOJ – Siewert 2 45 (54) 34 (30⋅4) 17 (37)
Not recorded 0 (0) 6 (5⋅4) 1 (2)
Operative approach THO 23 (27) 43 (38⋅4) 16 (35) 0⋅068
LTA 23 (27) 36 (32⋅1) 8 (17)
ILO 37 (44) 29 (25⋅9) 21 (46)
McKeown/3-stage 1 (1) 4 (3⋅6) 1 (2)
Clinical T category† cT0–2 15 (18) 13 (11⋅6) 4 (9) 0⋅578
cT3–4 69 (82) 99 (88⋅4) 42 (91)
Clinical N category† cN0 16 (19) 23 (20⋅5) 4 (9) 0⋅108
cN1 55 (65) 63 (56⋅3) 30 (65)
cN2 12 (14) 21 (18⋅8) 10 (22)
cN3 1 (1) 5 (4⋅5) 2 (4)
NAC given Yes 71 (85) 103 (92⋅0) 46 (100) 0⋅102
No 13 (15) 9 (8⋅0) 0 (0)
NAC agent CF 6 (8) 4 (3⋅9) 3 (7) 0⋅268
ECF 15 (21) 14 (13⋅6) 8 (17)
ECX 33 (46) 62 (60⋅2) 25 (54)
EOX 3 (4) 7 (6⋅8) 4 (9)
Other 8 (11) 12 (11⋅7) 4 (9)
Not recorded 6 (8) 4 (3⋅9) 2 (4)
Pathological T category† pT0–2 19 (23) 9 (8⋅0) 6 (13) 0⋅032
pT3–4 65 (77) 103 (92⋅0) 40 (87)
Pathological N category† pN0 18 (21) 24 (21⋅4) 8 (17) 0⋅406
pN1 12 (14) 25 (22⋅3) 17 (37)
pN2 30 (36) 30 (26⋅8) 13 (28)
pN3 24 (29) 33 (29⋅5) 8 (17)
Postoperative differentiation Well/moderate 33 (39) 52 (46⋅4) 17 (37) 0⋅318
Poor 51 (61) 60 (53⋅6) 29 (63)
Mandard grade TRG 1–3 12 (17) 18 (17⋅5) 16 (35) 0⋅923
TRG 4–5 57 (80) 81 (78⋅6) 30 (65)
Not recorded 2 (3) 4 (3⋅9) 0 (0)
Lymph node yield* 21 (16–26) 21 (15–27) 26 (20–32) 0⋅970§
No. of positive lymph nodes* 4 (1–9) 3 (1–7) 2 (1–4) 0⋅146§
Margin type Radial only 73 (87) 92 (82⋅1) 39 (85) 0⋅989
Longitudinal only 1 (1) 3 (2⋅7) 3 (7)
Both 9 (11) 16 (14⋅3) 4 (9)
Positive (position unknown) 1 (1) 1 (0⋅9) 0 (0)
Lymphovascular invasion Yes 63 (75) 80 (71⋅4) 28 (61) 0⋅577
No 21 (25) 32 (28⋅6) 18 (39)
Recurrence pattern Local 8 (18) 15 (25) 5 (21) 0⋅486
Systemic 24 (55) 33 (56) 14 (58)
Mixed 12 (27) 11 (19) 5 (21)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †TNM classification, 7th edition. GOJ, gastro-oesophageal
junction; THO, transhiatal oesophagectomy; LTA, left thoracoabdominal oesophagectomy; ILO, Ivor Lewis oesophagectomy; NAC, neoadjuvant
chemotherapy; CF, cisplatin and 5-fluorouracil; ECF, epirubicin, cisplatin and 5-fluorouracil; ECX, epirubicin, cisplatin and capecitabine; EOX, epirubicin,
oxaliplatin and capecitabine; TRG, tumour regression grade. ‡Comparison of adjuvant chemoradiotherapy versus no adjuvant treatment; χ2 test, except
§Kruskal–Wallis test.
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P = 0⋅154 (log rank test).
Table 2 Crude and adjusted Cox regression analyses for overall survival in patients who underwent margin-positive resection stratified
by response to neoadjuvant treatment
Crude analysis Adjusted analysis
Hazard ratio P Hazard ratio P
All patients
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅76 (0⋅53, 1⋅08) 0⋅122 0⋅71 (0⋅47, 1⋅06) 0⋅097
Adjuvant chemotherapy 0⋅67 (0⋅42, 1⋅06) 0⋅086 0⋅64 (0⋅39, 1⋅04) 0⋅072
Mandard TRG 1–3, responder
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅83 (0⋅29, 2⋅43) 0⋅739 0⋅64 (0⋅15, 2⋅71) 0⋅541
Adjuvant chemotherapy 1⋅66 (0⋅60, 4⋅53) 0⋅327
Mandard TRG 4–5, non-responder
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅68 (0⋅45, 1⋅01) 0⋅060 0⋅61 (0⋅38, 0⋅97) 0⋅037
Adjuvant chemotherapy 0⋅46 (0⋅26, 0⋅80) 0⋅007 0⋅44 (0⋅24, 0⋅80) 0⋅008
Values in parentheses are 95 per cent confidence intervals. Stratified models were adjusted for age (continuous), sex, tumour location (oesophageal, Siewert 1,
Siewert 2), pathological T category (pT0–2, pT3–4), pathological N category (pN0, pN1, pN2, pN3), lymphovascular invasion, postoperative differen-
tiation (well/moderate, poor), and operative approach (Ivor Lewis oesophagectomy, transhiatal oesophagectomy, left thoracoabdominal oesophagectomy).
TRG, tumour regression grade.
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 1801–1810
on behalf of BJS Society Ltd.
1806 R. K. Bott, K. Beckmann, J. Zylstra, M. J. Wilkinson, W. R. C. Knight, C. R. Baker et al.













































P = 0⋅168 (log rank test).
and 5) treated with adjuvant chemoradiotherapy versus no
adjuvant treatment (HR 0⋅61, 0⋅38 to 0⋅97; P= 0⋅037); a
survival benefit was also seen with adjuvant chemotherapy
(HR 0⋅44, 0⋅24 to 0⋅80; P= 0⋅008).
Recurrence-free survival
Fig. 2 shows Kaplan–Meier curves for recurrence-free sur-
vival by adjuvant therapy type. Results of Cox regres-
sion analyses of recurrence-free survival are presented in
Table 3 and Table S2 (supporting information). Patholog-
ical N3 status (HR 5⋅63, 95 per cent c.i. 2⋅82 to 11⋅20;
P < 0⋅001) was also independently associated with poor
recurrence-free survival. Adjuvant treatment was associ-
ated with improved recurrence-free survival in adjusted
analyses (adjuvant chemoradiotherapy: HR 0⋅59, 0⋅38 to
0⋅94, P= 0⋅026; adjuvant chemotherapy: HR 0⋅57, 0⋅33 to
0⋅98, P= 0⋅044). In analyses stratified by tumour response
to neoadjuvant chemotherapy, the survival benefit from
adjuvant chemoradiotherapy was observed specifically in
non-responders (HR 0⋅53, 0⋅31 to 0⋅90; P= 0⋅014), but not
in responders (HR 0⋅72, 0⋅15 to 3⋅43; P= 0⋅687).
Recurrence patterns
The association between adjuvant therapy and risk of dif-
ferent recurrence patterns is shown in Table 4. A survival
benefit from adjuvant chemoradiotherapy was noted in all
patients (responders and non-responders) for local (HR
0⋅48, 95 per cent c.i. 0⋅24 to 0⋅99; P= 0⋅047) and systemic
(HR 0⋅56, 0⋅33 to 0⋅94; P= 0⋅027) recurrence.
Impact of patient fitness
Subgroup analysis of patients with available data on ASA
fitness grade demonstrated an overall survival benefit (HR
0⋅68, 95 per cent c.i. 0⋅46 to 0⋅98; P= 0⋅041) and a
recurrence-free survival benefit (HR 0⋅59, 0⋅39 to 0⋅90;
P= 0⋅015) for adjuvant treatment, after adjustment for ASA
grade as an additional confounder.
Impact of margin involvement definition
Among 155 patients with data available on distance to
margin who underwent R1 resection by RCP criteria, 95
(61⋅3 per cent) had negative margins according to the
CAP definition, whereas 60 (38⋅7 per cent) had positive
margins. Survival analysis stratified by margin definition
showed similar results, although the HRs for adjuvant
chemoradiotherapy versus no treatment were lower in the
CAP positive-margin group (overall survival: HR 0⋅58,
95 per cent c.i. 0⋅25 to 1⋅34, P= 0⋅206; recurrence-free
survival: HR 0⋅38, 0⋅12 to 1⋅22, P= 0⋅106) than in the
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 1801–1810
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Table 3 Crude and adjusted Cox regression analyses for recurrence-free survival in patients who underwent margin-positive resection
stratified by response to neoadjuvant treatment
Crude analysis Adjusted analysis
Hazard ratio P Hazard ratio P
All patients
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅72 (0⋅49, 1⋅06) 0⋅099 0⋅59 (0⋅38, 0⋅94) 0⋅026
Adjuvant chemotherapy 0⋅67 (0⋅41, 1⋅11) 0⋅123 0⋅57 (0⋅33, 0⋅98) 0⋅044
Mandard TRG 1–3, responder
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅79 (0⋅27, 2⋅27) 0⋅655 0⋅72 (0⋅15, 3⋅43) 0⋅687
Adjuvant chemotherapy 0⋅71 (0⋅23, 2⋅20) 0⋅552 0⋅84 (0⋅12, 10⋅8) 0⋅903
Mandard TRG 4–5, non-responder
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅64 (0⋅41, 1⋅00) 0⋅051 0⋅53 (0⋅31, 0⋅90) 0⋅014
Adjuvant chemotherapy 0⋅63 (0⋅34, 1⋅05) 0⋅111 0⋅56 (0⋅30, 1⋅05) 0⋅071
Values in parentheses are 95 per cent confidence intervals. Stratified models were adjusted for age (continuous), sex, tumour location (oesophageal, Siewert
1, Siewert 2), pathological T category (pT0–2, pT3–4), pathological N category (pN0, pN1, pN2, pN3), lymphovascular invasion, postoperative differen-
tiation (well/moderate, poor), and operative approach (Ivor Lewis oesophagectomy, transhiatal oesophagectomy, left thoracoabdominal oesophagectomy).
TRG, tumour regression grade.
Table 4 Crude and adjusted Cox regression analyses by recurrence pattern in patients who underwent margin-positive resection
stratified by response to neoadjuvant treatment
Local recurrence Systemic recurrence
Hazard ratio P Hazard ratio P
All patients
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅48 (0⋅24, 0⋅99) 0⋅047 0⋅56 (0⋅33, 0⋅94) 0⋅027
Adjuvant chemotherapy 0⋅45 (0⋅19, 1⋅05) 0⋅064 0⋅62 (0⋅34, 1⋅13) 0⋅117
Mandard TRG 1–3, responder
No adjuvant therapy 1⋅00 (reference)
Adjuvant chemoradiotherapy 1⋅12 (0⋅20, 6⋅35) 0⋅898
Adjuvant chemotherapy 1⋅28 (0⋅15, 11⋅3) 0⋅823
Mandard TRG 4–5, non-responder
No adjuvant therapy 1⋅00 (reference) 1⋅00 (reference)
Adjuvant chemoradiotherapy 0⋅48 (0⋅22, 1⋅06) 0⋅069 0⋅48 (0⋅26, 0⋅88) 0⋅017
Adjuvant chemotherapy 0⋅53 (0⋅21, 1⋅30) 0⋅166 0⋅58 (0⋅28, 1⋅18) 0⋅135
Values in parentheses are 95 per cent confidence intervals. Stratified models were adjusted for age (continuous), sex, tumour location (oesophageal, Siewert
1, Siewert 2), pathological T category (pT0–2, pT3–4), pathological N category (pN0, pN1, pN2, pN3), lymphovascular invasion, postoperative differen-
tiation (well/moderate, poor), and operative approach (Ivor Lewis oesophagectomy, transhiatal oesophagectomy, left thoracoabdominal oesophagectomy).
TRG, tumour regression grade.
intermediate CAP negative-margin, RCP positive-margin
group (overall survival HR 0⋅80, 0⋅36 to 1⋅74, P= 0⋅579;
recurrence-free survival: HR 0⋅58, 0⋅23 to 1⋅45, P= 0⋅214).
Propensity score-matched survival analyses
Kaplan–Meier curves for overall and recurrence-free sur-
vival in the propensity score-matched subgroups are shown
in Figs S1 and S2 (supporting information), and the results
of regression analyses in Table 5. An overall survival bene-
fit (HR 0⋅62, 95 per cent c.i. 0⋅39 to 0⋅98; P= 0⋅042) and
recurrence-free survival benefit (HR 0⋅51, 0⋅30 to 0⋅87;
P= 0⋅004) was observed for adjuvant chemoradiotherapy
versus no adjuvant treatment. Adjuvant chemotherapy did
not have a significant benefit compared with no adjuvant
treatment in terms of overall survival (HR 0⋅64, 0⋅37 to
1⋅10; P= 0⋅105) or recurrence-free survival (HR 0⋅63, 0⋅34
to 1⋅15; P= 0⋅130).
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Table 5 Cox proportional hazards regression analysis comparing effects of adjuvant treatments on overall survival and recurrence-free
survival in propensity score-matched cohorts of patients who underwent margin-positive resection
Death Recurrence
Hazard ratio P Hazard ratio P
Adjuvant chemoradiotherapy (n= 53) versus no adjuvant treatment (n= 78) 0⋅62 (0⋅39, 0⋅98) 0⋅042 0⋅51 (0⋅30, 0⋅87) 0⋅004
Adjuvant chemotherapy (n= 31) versus no adjuvant treatment (n= 76) 0⋅64 (0⋅37, 1⋅10) 0⋅105 0⋅63 (0⋅34, 1⋅15) 0⋅130
Values in parentheses are 95 per cent confidence intervals.
Discussion
The present results suggest that adjuvant chemoradiother-
apy improves survival in patients with positive margins after
surgical resection for oesophageal adenocarcinoma. This
benefit was most pronounced in non-responders to neoad-
juvant chemotherapy. A survival benefit was observed in
terms of both local and systemic recurrence.
There are some methodological constraints which merit
consideration. Ideally, prospective randomized data would
guide therapeutic strategies in this patient group, yet few
previous studies have specifically examined the role of adju-
vant therapy in oesophageal cancer. Although retrospective
in nature, this large cohort study combined the results of
consecutive patients treated in two high-volume special-
ist institutions. Although this may offer a more realistic
reflection of contemporaneous practice, it remains impos-
sible to completely eliminate bias in studies of this kind,
despite adjusting for confounding factors. Although data
from two institutions were included, both assumed the
same MDT process using very similar, evidence-based pro-
tocols for perioperative treatment decisions. The neoadju-
vant and adjuvant regimens varied slightly over the course
of the study, reflecting real-time working practice, and this
is unlikely to have affected the overall study conclusions.
At the outset, all patients were scheduled to receive three
cycles of postoperative chemotherapy according to the
MAGIC regimen4. In UK practice, patients with a micro-
scopically positive resection margin are generally consid-
ered for additional adjuvant radiotherapy as they have an
increased risk of developing recurrence19. In this study,
84 patients (34⋅7 per cent) did not receive any postoper-
ative treatment, despite having pathological staging that
was equivalent to that in patients who did. As in other
studies, this was most commonly owing to patient fitness
and/or poor tolerance of neoadjuvant chemotherapy. The
survival benefit seen for adjuvant chemoradiotherapy could
have been a result of selection bias for patients who were
medically fitter and more tolerant of perioperative treat-
ments. This bias was mitigated by use of adjusted analyses
(including patient age and ASA grade), and by using cohorts
matched for a variety of patient, staging and tumour
characteristics. Additional propensity score-matched anal-
ysis was included as this was considered to be the standard
statistical method for comparing different treatments in
retrospective populations20. Although overall survival may
conceivably have been influenced by poorer fitness in the
group that did not receive adjuvant treatment, the fact that
cancer-specific survival and both locoregional and systemic
recurrence rates were all improved by adjuvant treatment
would suggest this to be a genuine oncological benefit.
Forty-six patients (19⋅0 per cent) were treated with adju-
vant chemotherapy alone. Chemoradiotherapy had been
recommended for most of these patients but they did
not receive the radiotherapy component, most commonly
because of side-effects or complications of chemotherapy.
This highlights an interesting area for future work, beyond
the scope of the present study, to examine in greater detail
which patients derive benefit from the adjuvant chemother-
apy and radiotherapy components respectively.
The histological Mandard TRG was used as a marker of
response to neoadjuvant chemotherapy; although this has
been shown to be prognostic in patients with oesophageal
cancer treated by neoadjuvant chemotherapy, it remains
imperfect in identifying all true responders. Tumour
downstaging21 and lymph node regression22 may provide
important supplementary information that could be used
to guide treatment decisions in these patients. Classifying
patients as responders or non-responders remains logical,
although to which group patients with a TRG of 3 should
be allocated remains contentious23.
Currently, there is no clear evidence from RCTs regard-
ing the survival benefit of adjuvant treatment after surgical
resection for oesophageal adenocarcinoma. Ongoing trials
may help determine the role of postoperative treatment
in these patients. At present, observational studies provide
the available evidence to guide treatment decisions, and
such studies are mostly small and from single institutions.
However, there appears to be a trend towards better
survival outcomes with adjuvant treatment. A number of
studies have demonstrated improved survival in patients
with gastro-oesophageal adenocarcinoma who continued
ECF chemotherapy after surgery24,25. A European study26
of 134 patients treated with ECF, EOX and FLOT showed
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2020; 107: 1801–1810
on behalf of BJS Society Ltd.
Adjuvant therapy in oesophageal adenocarcinoma 1809
that the survival benefit of continuing chemotherapy
after surgical resection was limited to patients with
node-positive tumours and poor histological regression.
This was at odds with the findings of a study23 from the
UK that demonstrated improved survival in patients with
chemotherapy-responsive cancers (Mandard TRG 1–3).
That study reported no clear survival benefit in patients
with non-responsive tumours (Mandard TRG 4 and 5), a
finding that might be considered more logical as continu-
ation of a treatment shown to be ineffective histologically
is unlikely to be of benefit to the patient. Another recent
UK study3, which also used propensity score-matched
analysis, concluded that only patients with a positive mar-
gin after surgery (R1 resection) benefited from continuing
chemotherapy after operation. Both overall survival and
time to relapse improved in that study3. Two further
retrospective studies27,28 suggested a potential benefit of
adjuvant chemoradiotherapy compared with no adjuvant
treatment in patients with positive margins (R1 resection).
In the context of the available literature, the present study
has provided evidence of a survival benefit for adjuvant
chemoradiotherapy and chemotherapy in patients with
positive resection margins, particularly in non-responders
to neoadjuvant chemotherapy. That the addition of radio-
therapy to a surgical field with an involved resection mar-
gin might improve locoregional recurrence rates would be
logical, as would the idea that the patients who gain most
benefit from a change in treatment strategy would be those
who did not respond well to chemotherapy before surgery.
Why these patients also appeared to benefit in terms of sys-
temic recurrence remains unclear; however, there is some
evidence to suggest that there may be tumour regression
at non-irradiated sites in addition to the irradiated tumour
site itself, the so-called abscopal effect29,30.
Questions that remain pertinent are whether patients
with clear margins should be offered adjuvant treatment,
and how to individualize therapy more effectively to gain
the benefit of additional treatment in suitable patients
while avoiding unnecessary toxicities in those who do not
respond.
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